A Phase 4 interventional study of ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed and BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed in Pertussis, Tetanus and Diphtheria, sponsored by Sanofi. Completed at 10 sites in United States. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-05.
Sponsored by Sanofi · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing adacel in Whooping Cough — none open to participants now, none under way, none of them phase 3. adacel · Whooping Cough.
Among the 24 studies testing adacel in Whooping Cough, this one is the 10th largest by enrollment, is one of 6 that started in 2006, is one of 14 in phase 4, and was the 3rd registered.
290 studies on the registry are indexed under Whooping Cough; 23 are open to participants now.
Browse Whooping Cough studies →None of the 24 studies testing adacel in Whooping Cough is open now. The open studies under Whooping Cough, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 14 Whooping Cough studies recruiting now, 2 (14%) set no upper age limit and 11 (79%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 11 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 7 · Phase 4 14
First in 2005; this study’s year is marked. 6 started in 2006.
This study's enrollment of 647 is above the median of 400 across 228 interventional studies indexed under Whooping Cough.
Median enrollment 523 across the 24 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 24 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
82 studies in Whooping Cough by Sanofi: none open now, 1 under way, none of them phase 3. Of 81 finished, 46 (57%) have results posted.
Among the 82 studies in Whooping Cough by Sanofi, this one is the 32nd largest by enrollment of the 71 interventional ones that give a count, is one of 19 that started in 2006, is one of 18 in phase 4, and was the 14th registered.
Sanofi’s Whooping Cough studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing adacel in Whooping Cough, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 82 in Whooping Cough:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a descriptive study to evaluate the safety and immunogenicity of ADACEL® and BOOSTRIX® vaccines among US adolescents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Serious chronic disease (i.e. cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc) that is unstable or that might:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Biological: BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix®
Solicited injection site reactions: Pain, Erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia. Grade 3 reaction definitions: Pain = Incapacitating, unable to perform usual activities; Erythema and swelling = ≥ 5 cm; Fever = temperature ≥ 39.1°C or ≥ 102.3°F; Headache, Malaise, and Myalgia = Prevents daily activities.
Time frame: Day 0 to 7 post-vaccination
Percentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.
Time frame: Day 0 and 28 days post-vaccination
Percentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.
Time frame: Day 0 and 28 days post-vaccination
Geometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination With Adacel® or Boostrix®.
Time frame: Day 0 and 28 days post-vaccination
Participants were enrolled from 09 May 2006 to 02 October 2006 in 12 clinical centers in the US.
| Milestone | Adacel® Vaccine Group | Boostrix® Vaccine Group |
|---|---|---|
| Started | 323 | 321 |
| Completed | 319 | 317 |
| Not completed | 4 | 4 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Solicited injection site reactions: Pain, Erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia. Grade 3 reaction definitions: Pain = Incapacitating, unable to perform usual activities; Erythema and swelling = ≥ 5 cm; Fever = temperature ≥ 39.1°C or ≥ 102.3°F; Headache, Malaise, and Myalgia = Prevents daily activities.
| Participants | Adacel® Vaccine Group | Boostrix® Vaccine Group |
|---|---|---|
| Any solicited injection site reaction | 273 | 257 |
| Grade 3 solicited injection site reaction | 5 | 4 |
| Any solicited injection site Pain | 270 | 247 |
| Grade 3 solicited inj. site Pain (Incapacitating) | 2 | 3 |
| Any solicited injection site Erythema | 75 | 67 |
| Grade 3 solicited injection site Erythema (≥ 5 cm) | 2 | 1 |
| Any solicited injection site Swelling | 61 | 44 |
| Grade 3 solicited injection site Swelling (≥ 5 cm) | 2 | 1 |
| Any solicited systemic reaction | 216 | 205 |
| Grade 3 solicited systemic reaction | 9 | 9 |
| Any solicited Fever | 18 | 9 |
| Grade 3 solicited Fever (≥ 39.1°C or ≥ 102.3°F) | 1 | 0 |
| Any solicited Headache | 136 | 108 |
| Gr 3 solicited Headache: Prevents daily activities | 3 | 4 |
| Any solicited Malaise | 91 | 78 |
| Gr 3 solicited Malaise: Prevents daily activities | 8 | 6 |
| Any solicited Myalgia | 167 | 166 |
| Gr 3 solicited Myalgia: Prevents daily activities | 1 | 3 |
| Percentage of Participants | Adacel® Vaccine Group | Boostrix® Vaccine Group |
|---|---|---|
| Tetanus IgG antitoxin ≥0.1 IU/mL :pre-vaccination | 99 | 98 |
| Tetanus IgG antitoxin ≥0.1 IU/mL :28 days post-vac | 100 | 100 |
| Percentage of Participants | Adacel® Vaccine Group | Boostrix® Vaccine Group |
|---|---|---|
| Diphtheria IgG antitoxin ≥0.1 IU/mL : pre-vacc | 92 | 93 |
| Diphtheria IgG antitoxin ≥0.1 IU/mL: 28 D post-vac | 100 | 100 |
| EU/mL | Adacel® Vaccine Group | Boostrix® Vaccine Group |
|---|---|---|
| Anti-pertussis toxoid IgG: pre-vaccination | 14.4 (12.5 to 16.6) | 13.5 (11.6 to 15.8) |
| Anti-filamentous hemagglutinin IgG:pre-vaccination | 26.1 (22.7 to 30.0) | 28.2 (24.5 to 32.4) |
| Anti-pertactin IgG: pre-vaccination | 12.4 (10.6 to 14.6) | 13.1 (11.2 to 15.5) |
| Anti-fimbriae types 2 and 3 IgG: pre-vaccination | 13.9 (12.0 to 16.2) | 14.5 (12.2 to 17.2) |
| Anti-pertussis toxoid IgG: post-vaccination | 86.7 (78.8 to 95.4) | 135.9 (122.9 to 150.2) |
| Anti-filamentous hemagglutinin IgG post-vaccinat. | 240.7 (217.7 to 266.1) | 402.9 (365.5 to 444.2) |
| Anti-pertactin IgG: post-vaccination | 322.7 (279.7 to 372.4) | 463.3 (395.4 to 542.9) |
| Anti-fimbriae types 2 and 3 IgG: post-vaccination | 1203 (1004 to 1442) | 26.6 (22.2 to 31.8) |
Collected over Adverse events data were collected from the day of vaccination up to 1 month post-vaccination.. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adacel® Vaccine Group | — | 0/323 (0%) | 273/320 (85.3%) |
| Boostrix® Vaccine Group | — | 0/321 (0%) | 257/317 (81.1%) |
| Event | Adacel® Vaccine Group | Boostrix® Vaccine Group |
|---|---|---|
| Solicited injection site PainGeneral disorders | 270/320 | 257/317 |
| Solicited MyalgiaMusculoskeletal and connective tissue disorders | 167/320 | 166/317 |
| Solicited HeadacheNervous system disorders | 136/320 | 108/317 |
| Solicited MalaiseGeneral disorders | 91/320 | 78/317 |
| Solicited injection site ErythemaGeneral disorders | 75/320 | 67/316 |
| Solicited injection site SwellingGeneral disorders | 61/320 | 44/316 |
| Solicited FeverGeneral disorders | 18/320 | 9/316 |
| Age, Categorical(Participants) | Adacel® Vaccine Group | Boostrix® Vaccine Group | Total |
|---|---|---|---|
| <=18 years | 291 | 291 | 582 |
| Between 18 and 65 years | 32 | 30 | 62 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Adacel® Vaccine Group | Boostrix® Vaccine Group | Total |
|---|---|---|---|
| Mean | 14.5 ± 2.33 | 14.7 ± 2.33 | 14.6 ± 2.33 |
| Sex: Female, Male(Participants) | Adacel® Vaccine Group | Boostrix® Vaccine Group | Total |
|---|---|---|---|
| Female | 154 | 150 | 304 |
| Male | 169 | 171 | 340 |
| Region of Enrollment(participants) | Adacel® Vaccine Group | Boostrix® Vaccine Group | Total |
|---|---|---|---|
| United States | 323 | 321 | 644 |
The record gives a start of May 2006, a primary completion of Oct 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adacel · Boostrix